SHQ1-related neurodevelopmental disorder is a rare autosomal recessive condition linked to disrupted ribosome biogenesis, telomerase activity, and RNA modification. Among the few reported cases, typical clinical presentations consist of early-onset hypotonia, seizures, movement disorders, and progressive neurologic impairment. We present a male patient who, at 4 months, displayed global developmental delay, hypotonia, feeding difficulties, and impaired cervical motor control. He progressed to exhibit choreiform movements and oromotor hypotonia. Extensive metabolic and genetic workup was unrevealing; whole exome sequencing (WES) in 2022 was nondiagnostic, and supportive measures were continued. In 2024, WES reanalysis identified compound heterozygous variants in SHQ1, NM₀18130. 4: c. 523G>T (p. Gly175Cys) and NM₀18130. 4: c. 828₈31del (p. Glu276fs*12), both now recognized as pathogenic. Brain MRI was normal, and cerebrospinal fluid neurotransmitter analysis revealed reduced homovanillic acid, suggesting dopaminergic pathways. This case expands the clinical spectrum of SHQ1-related disorder by illustrating a milder phenotype with functional developmental gains and emphasis on the diagnostic value of WES reanalysis.
Ly et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: